Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of GcMAF in Chronic Inflammatory Diseases
NCT06877364Phase 2Completed
- Sponsor
- S-LAB
- Start
- Sep 2025
- Primary completion
- Sep 2025
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gcmaf in chronic inflammatory disease, rheumatoid arthritis (RA) and chronic cystitis (2 arms), sponsored by S-LAB. Primary endpoints: Number of Participants with Treatment-Emergent Adverse Events at 4 weeks and Disease Activity Score 28 at 16 weeks. Started Sep 2025; status: completed.
02
Drugs
gcmaf
03
Conditions
chronic inflammatory diseaserheumatoid arthritis (RA)chronic cystitis
Beyond the preview
Go deeper on NCT06877364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06877364.